MRK Jul 2024 123.000 call
| Previous Close | 6.17 |
| Open | N/A |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 123.00 |
| Expire Date | 2024-07-05 |
| Day's Range | 6.17 - 6.17 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ACCESSWIREMerck Is Partnering With America’s Largest HBCU To Launch a Collaborative Biotechnology Learning Center
NORTHAMPTON, MA / ACCESSWIRE / June 20, 2024 / Building the workforce of tomorrow means investing in the students of today. That's why Merck has partnered with North Carolina Agricultural and Technical State University (N.C. A&T) - the largest historically ...
- Yahoo Finance Video
FDA approves Merck's pneumonia vaccine for adults
The Food and Drug Administration (FDA) has approved Merck's (MRK) new vaccine to protect adults from pneumonia. Yahoo Finance's Anjalee Khemlani reports more on how the vaccine works as the pharmaceutical company awaits the Centers for Disease Control's (CDC) recommendation. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
ZacksMerck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
